Results from AceLink’s Phase 2 AL01211 Study in Fabry Disease Presented at WORLD Symposium 2025 AceLink Therapeutics, a clinical-stage biotech firm focused on developing next-generation oral substrate reduction therapies (SRTs), presented interim results from its ongoing Phase 2 clinical study…
Agreement Terminated: Devonian Health Group Ends Distribution Deal Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage company focused on developing innovative solutions for inflammatory diseases, announced that its pharmaceutical distribution division, Altius Health Group…
Crown Laboratories Finalizes Acquisition of Revance Therapeutics Crown Laboratories, Inc., a global leader in innovative skincare solutions and a part of the Hildred Capital portfolio, has officially closed its acquisition of Revance Therapeutics, Inc., a biotechnology company focused on advancing…
Cyclo Therapeutics Presents Positive Phase 3 TransportNPC™ Data in Children Under 3 Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company focused on developing life-changing treatments for patients with rare and challenging diseases, today announced the presentation of data from…
Conference: Certis Oncology CEO Presents at 24th Annual Precision World Medicine Certis Oncology Solutions, a leader in precision oncology and translational science, recently showcased its groundbreaking advancements in artificial intelligence (AI) and machine learning (AI/ML) at the 24th Annual Precision…
Transplant of Genetically Engineered Porcine Kidney Successfully Performed in Second Patient by eGenesis eGenesis, a biotechnology firm focused on developing human-compatible engineered organs to help alleviate the global organ shortage, has announced the successful transplantation of a genetically engineered porcine…
Webinar on Ataxia-Telangiectasia Unmet Need Hosted by Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on advancing treatments for rare diseases, has announced that it will host an investor webinar today, Friday, February 7, 2025, at…
BlueWind Medical Announces Two-Year Durability Data for Revi® System BlueWind Medical, Ltd., a pioneer in implantable Tibial NeuroModulation (iTNM) therapies, announced today the publication of the two-year results from its pivotal OASIS study in the Journal of Urology (March 2025…
Announces Debt Exchange by Guardant Health Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, has announced a strategic move to strengthen its financial position through a debt exchange transaction. On February 6, 2025, the company entered into privately…
Agreement Secures DarioHealth’s Expansion in $1.2 Trillion Cardiometabolic Market DarioHealth Corp. (Nasdaq: DRIO) has secured a significant new agreement with a Blue Cross Blue Shield (BCBS) health plan, marking a crucial expansion in the rapidly growing digital health sector. This…
Reports Fortive Q4 and 2024 Results, Updates 2025 Outlook Fortive Corporation (NYSE: FTV) has announced its financial results for the fourth quarter and full year of 2024, highlighting strong growth across several segments and a positive outlook for 2025. The…
Nephritis in Active Lupus: Gazyva’s Superiority Proven in NEJM Dat Genentech, a member of the Roche Group, announced that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in patients with active lupus nephritis (LN) has been…